Coagulation disorders in patients with cirrhosis and severe sepsis

被引:92
作者
Plessier, A
Denninger, MH
Consigny, Y
Pessione, F
Francoz, C
Durand, F
Francque, S
Bezeaud, A
Chauvelot-Moachon, L
Lebrec, D
Valla, DC
Moreau, R [1 ]
机构
[1] Hop Beaujon, INSERM, U481, Lab Hemodynam Splanchn & Biol Vasc, F-92118 Clichy, France
[2] Hop Beaujon, Serv Hepatol, F-92118 Clichy, France
[3] Hop Beaujon, Serv Hematol & Immunol, F-92118 Clichy, France
[4] Estab Francais Greffes, Paris, France
[5] Hop Cochin, Dept Pharmacol, F-75674 Paris, France
关键词
cirrhosis; organ failure; sepsis;
D O I
10.1111/j.1478-3231.2003.00870.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: In patients with cirrhosis, severe sepsis may stimulate the extrinsic coagulation pathway resulting in thrombin generation and fibrin formation. Aims: To compare 23 patients with severe sepsis to 13 infected patients without severe sepsis and 18 patients without infection. Methods: Zymogen forms of clotting factors involved in the extrinsic pathway (i.e., factors VII+X, V, prothrombin), and the presence of soluble fibrin were assessed. Results: Zymogen forms of clotting factors were significantly lower, while Child-Pugh score and the proportion of patients with soluble fibrin were higher in the severe-sepsis group than in the other groups. Decreased zymogen levels were independently correlated with an elevated Child-Pugh score and the presence of severe sepsis. In the severe-sepsis group, after adjustment for the severity of cirrhosis, decreased zymogen levels were associated with significant increases in the relative risk ratios of in-hospital death. Conclusions: Cirrhotic patients with severe sepsis have decreased blood levels of zymogen forms of factors VII+X, V, and prothrombin, which may be due not only to the severity of cirrhosis but also, at least in part, to the consumption of these zymogens by the extrinsic coagulation pathway.
引用
收藏
页码:440 / 448
页数:9
相关论文
共 28 条
[1]  
Abraham E, 1998, LANCET, V351, P929
[2]   Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure [J].
Abraham, E ;
Naum, C ;
Bandi, V ;
Gervich, D ;
Lowry, SF ;
Wunderink, R ;
Schein, RM ;
Macias, W ;
Skerjanec, S ;
Dmitrienko, A ;
Farid, N ;
Forgue, ST ;
Jiang, F .
CRITICAL CARE MEDICINE, 2003, 31 (03) :718-728
[3]  
Afessa B, 2000, AM J GASTROENTEROL, V95, P484
[4]   Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients [J].
Alberti, C ;
Brun-Buisson, C ;
Goodman, SV ;
Guidici, D ;
Granton, J ;
Moreno, R ;
Smithies, M ;
Thomas, O ;
Artigas, A ;
Le Gall, JR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (01) :77-84
[5]   Coagulation disorders in liver disease [J].
Amitrano, L ;
Guardascione, MA ;
Brancaccio, V ;
Balzano, A .
SEMINARS IN LIVER DISEASE, 2002, 22 (01) :83-96
[6]   E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis - A randomized controlled trial [J].
Angus, DC ;
Birmingham, MC ;
Balk, RA ;
Scannon, PJ ;
Collins, D ;
Kruse, JA ;
Graham, DR ;
Dedhia, HV ;
Homann, S ;
MacIntyre, N .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (13) :1723-1730
[7]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[8]   AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[9]   Thrombin signalling and protease-activated receptors [J].
Coughlin, SR .
NATURE, 2000, 407 (6801) :258-264
[10]   Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? [J].
Esmon, CT .
BLOOD, 2000, 95 (04) :1113-1116